The Motley Fool

Beat A Volatile FTSE 100 With GlaxoSmithKline plc, Smith & Nephew plc, WPP PLC And Glencore PLC

While the FTSE 100 gained a boost from the Conservative election victory, its medium-term outlook may be somewhat uncertain. That’s because, while the UK economy is performing well, the EU referendum could take place next year and, between now and then, the political and investment outlook could change immensely.

Defensive Stocks

For example, the debate surrounding the yes/no question has the potential to cause serious upheaval in the Conservative party. That’s because it remains split on the European question (as it has done for many years), with there being a very real prospect of unrest among backbenchers should the concessions negotiated by David Cameron prove to be insufficient. And, with the prospect of the UK ending up outside of the EU unlikely to improve investor sentiment, defensive stocks such as GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) could be a great place to invest.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Clearly, GlaxoSmithKline’s future growth prospects have a relatively low correlation with the political events and economic outlook for the UK economy. So, there is a good chance that it will outperform the wider index moving forward, as investors seek out defensive stocks. Moreover, GlaxoSmithKline has a bright future, with an improving pipeline and major cost reductions having the potential to return the company to bottom line growth next year after a handful of challenging years.

Another excellent defensive play is Smith & Nephew (LSE: SN). Unlike GlaxoSmithKline, it has an excellent track record of earnings growth, with its bottom line having risen in each of the last five years and averaging growth of 5% per annum during the period. And, looking ahead, it offers relative stability due to consistent demand for its wound care, endoscopy and orthopaedic products, with its bottom line due to rise by as much as 13% next year.

International Exposure

Another company that may see investor sentiment improve over the medium term is WPP (LSE: WPP). While the UK is a key market for the company, it is very much an international play and is often viewed as a barometer of the global economy. And, with the US economy going from strength to strength and China also initiating a series of interest rate cuts in an attempt to stimulate the economy, WPP could see its profit rise at a brisk pace over the next couple of years. And, with it trading on a price to earnings (P/E) ratio of 16.4, it seems to offer good value for money, too.

Also having little reliance upon the UK economy is global mining play, Glencore (LSE: GLEN). Its share price is much more closely linked to the price and outlook for commodities rather than whether the UK remains in the EU or not. And, with it having a strong management team and a dividend yield of 4%, investor sentiment in the company could improve moving forward. That’s especially the case since Glencore currently pays out just 52% of profit as a dividend, which indicates that there is considerable scope for improved income levels moving forward.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.